The net profit of 9 Chinese medicine companies exceeded 100%!

Medical Network, March 4, March 2nd, the National Medical Products Administration approved the Qingfei Paidu Granules of the Institute of Basic Clinical Medicine of Chinese Academy of Chinese Medical Sciences, the Huashibaidu Granules of Guangdong Yifang Pharmaceutical Co.
, Ltd.
through special approval procedures.
Xuanfeibaidu Granules of Shandong Buchang Pharmaceutical Co.
, Ltd.
went on the market.
Since the outbreak of the new crown pneumonia epidemic, many academicians and experts in the Wuhan anti-epidemic clinical field have screened the results of effective prescriptions.
It is also the first time after the reform of the registration classification of Chinese medicines in accordance with the "Registration Classification and Application Information Requirements of Chinese Medicines" (No.
68, 2020).
No.
) "Class 3.
2 other traditional Chinese medicine compound preparations derived from ancient classic prescriptions" review and approval varieties.

 

The industry generally believes that the revision of the classification of Chinese medicine registration is expected to fundamentally solve key problems such as the obvious lack of motivation for innovation and development of Chinese medicine in recent years, and the Chinese medicine industry will usher in new development opportunities.
During the COVID-19 pandemic, traditional Chinese medicine relied on its unique advantages to become a formidable force in the fight against the epidemic.
Driven by the epidemic, the performance of listed Chinese medicine companies has improved dazzlingly.
According to the Beijing News, as of March 2, 38 Chinese medicine companies have released 2020 performance forecasts, performance reports or annual reports.
Among them, Yabao Pharmaceutical, Zuoli Pharmaceutical, Yiling Pharmaceutical, Kang Enbei, and Jiaying The net profit of nine pharmaceutical companies (predicted) increased by more than 100% year-on-year.

 

Policy superimposed on epidemic situation, comprehensive view of performance of Chinese medicine companies

 

Looking at the Chinese medicine companies that have disclosed their performance so far, the most outstanding market performance is Yiling Pharmaceutical, which holds the anti-epidemic "net celebrity" Chinese medicine Lianhua Qingwen series products.
According to the performance report recently released by Yiling Pharmaceutical, the company will achieve a total operating income of 8.
736 billion yuan in 2020, a year-on-year increase of 49.
97%, leading the ranks of listed Chinese medicine companies.
The net profit attributable to shareholders of listed companies also reached 1.
220 billion yuan, a year-on-year increase of 101.
12%.

 

Some analysts pointed out that the outstanding performance of Yiling Pharmaceutical is obviously related to the rapid growth in sales revenue of Lianhua Qingwen products compared with the same period last year.
Yiling Pharmaceuticals admitted frankly that during the reporting period, the brand awareness of Lianhua Qingwen products has been greatly improved, the domestic market demand has increased significantly, and sales have been achieved in more than ten registered overseas countries.
However, it is worth noting that Yiling Pharmaceutical also stated that the first prize of the National Science and Technology Progress Award has also increased its influence in the cardiovascular and cerebrovascular products market, and the sales of its cardiovascular and cerebrovascular products have increased significantly.

 

　　The report card of Zuoli Pharmaceutical, which ranks second in the pre-increasing rate of net profit, is also remarkable.
Although the net profit attributable to shareholders of listed companies in 2020 is expected to be only 85 million to 95 million yuan, the year-on-year growth can reach 232.
12%-271.
2%.
Zuoli Pharmaceuticals stated in the performance forecast that taking advantage of the core products Wuling Capsules, Bailing Tablets, and Lingze Tablets to enter the National Essential Drug List, increasing market investment and the development and coverage of terminal medical institutions are the main factors for performance growth.
.
From the perspective of the industry, in the face of changes in the external environment, focusing on the main business and grasping policy opportunities are the keys to the rapid growth of Zuoli Pharmaceutical's performance.

 

　　Although the predicted performance of net profit of 400 million to 480 million yuan, a year-on-year increase of 215.
73% to 238.
88%, Conba also entered the queue with a net profit increase of more than 100%, but from the perspective of revenue, it has a year-on-year increase of 12 The decline of% is not optimistic.
This is closely related to the listing of Danshen Ligustrazine Injection, the main product of subsidiary Guizhou Beite Pharmaceutical, in the national key monitoring catalog of rational use of drugs and the policy of recalling the medical insurance catalog.
Severely affected by the policy, the sales revenue of this product in 2020 will drop by about 1.
27 billion yuan year-on-year, a decrease of about 91.
4%.
However, Conba is also actively seeking to break through.
In addition to proactively adjusting and optimizing its business and product structure, focusing on expanding the self-health product business including over-the-counter drugs and consumer health products, it is also accelerating the development of new online retail business and trying its best to digest the factors.
Negative effects caused by policies and the epidemic.

 

　　Representatives of the National People's Congress suggest speeding up the collection of traditional Chinese medicine and formula granules

 

　　Traditional Chinese medicine is the advantage and characteristic of my country's health undertakings.
With the support of many national and local policies, the Chinese medicine industry is continuously developing.
Public data shows that the market size of Chinese patent medicines has increased from 625.
2 billion yuan in 2015 to 814.
9 billion yuan in 2019.
In accordance with this trend, the industry expects that the market size of proprietary Chinese medicines in 2022 is expected to exceed the trillion yuan mark.

 

　　And the traditional Chinese medicine formula granules, which have been piloted for 20 years and will soon usher in "regularity", will undoubtedly add another heavy assist to the Chinese medicine industry.
In February this year, in order to strengthen the management of traditional Chinese medicine formula granules, standardize the production of Chinese medicine formula granules, guide the healthy development of the industry, and better meet the clinical needs of Chinese medicine, the State Food and Drug Administration, the State Administration of Traditional Chinese Medicine, the National Health Commission, and the National Medical Insurance Administration The department jointly issued the "Announcement on Ending the Pilot Work of Chinese Medicine Formula Granules" (No.
22 of 2021).
Chinese medicine formula granules are subject to record management and cannot be sold outside medical institutions.

 

　　According to the National Pharmacopoeia Commission, the draft national drug standard for 160 Chinese medicine formula granules has been publicized and will be submitted to the National Drug Administration for approval and promulgation in the near future.
Some analysts pointed out that the promulgation of national standards for Chinese medicine formula granules may change the competitive landscape of this tens of billions market.
At the time when the "Two Sessions" are about to begin, according to China Securities Network, the National People's Congress and Chenguang Bio-Chairman Lu Qingguo intends to make suggestions at this year's national "Two Sessions" to speed up the entry of Chinese medicines and formula particles into centralized procurement.

 

　　Lu Qingguo said that the production of traditional Chinese medicine is small, scattered, and chaotic.
A pharmaceutical factory has dozens of varieties and tens of millions of sales.
The phenomenon of vicious competition, low-level duplication, emphasis on marketing, neglect of technology, and neglect of management is widespread.
Government supervision has increased the workload and difficulty.
The implementation of centralized procurement bidding for traditional Chinese medicines can effectively promote the large-scale production and operation of traditional Chinese medicine companies, reduce the cost of traditional Chinese medicine drugs, and enable Chinese medicine companies to achieve healthy development while focusing on management and technological progress, thereby promoting the healthy development of the Chinese medicine industry.
The proposal is to create conditions as soon as possible to allow proprietary Chinese medicines to enter the mechanism of centralized drug bidding and procurement, so that more traditional Chinese medicine manufacturers can participate in the competition fairly; improve the standard system, include traditional Chinese medicine formula granules into the drug centralized pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding procurement system, and promote traditional Chinese medicine formulations Better development of particles.

 

　　From the perspective of the industry, the policy of mass procurement of drugs has achieved remarkable results.
It has not only greatly saved medical insurance expenses and solved the problem of falsely high drug prices, but also eliminated the prevalence of rebates in the process of drug purchase and sales and guided drug manufacturers to dilute marketing and strengthen management.
Play an important role.
Although Zhejiang Jinhua, Qinghai, Liaoning, Henan and other provinces and cities have all launched trials of mass procurement of proprietary Chinese medicines, which has provided necessary experience for the procurement of Chinese patent medicines into the country, the relevant person in charge of the National Medical Insurance Bureau also stated that biosimilars and proprietary Chinese medicines are included Centralized procurement is "no doubt", but at present, it remains to be seen by the industry whether the conditions and time for Chinese medicine and formula granules to enter mass procurement have matured.

 

　　Provincial documents and pilot enterprises of Chinese medicine formula granules in some provinces and cities in my country

　　Medical Network, March 4, March 2nd, the National Medical Products Administration approved the Qingfei Paidu Granules of the Institute of Basic Clinical Medicine of Chinese Academy of Chinese Medical Sciences, the Huashibaidu Granules of Guangdong Yifang Pharmaceutical Co.
, Ltd.
through special approval procedures.
Xuanfeibaidu Granules of Shandong Buchang Pharmaceutical Co.
, Ltd.
went on the market.
Since the outbreak of the new crown pneumonia epidemic, many academicians and experts in the Wuhan anti-epidemic clinical field have screened the results of effective prescriptions.
It is also the first time after the reform of the registration classification of Chinese medicines in accordance with the "Registration Classification and Application Information Requirements of Chinese Medicines" (No.
68, 2020).
No.
) "Class 3.
2 other traditional Chinese medicine compound preparations derived from ancient classic prescriptions" review and approval varieties.

 

　　The industry generally believes that the revision of the classification of Chinese medicine registration is expected to fundamentally solve key problems such as the obvious lack of motivation for innovation and development of Chinese medicine in recent years, and the Chinese medicine industry will usher in new development opportunities.
During the COVID-19 pandemic, traditional Chinese medicine relied on its unique advantages to become a formidable force in the fight against the epidemic.
Driven by the epidemic, the performance of listed Chinese medicine companies has improved dazzlingly.
According to the Beijing News, as of March 2, 38 Chinese medicine companies have released 2020 performance forecasts, performance reports or annual reports.
Among them, Yabao Pharmaceutical, Zuoli Pharmaceutical, Yiling Pharmaceutical, Kang Enbei, and Jiaying The net profit of nine pharmaceutical companies (predicted) increased by more than 100% year-on-year.

 

　　Policy superimposed on epidemic situation, comprehensive view of performance of Chinese medicine companies

 

　　Looking at the Chinese medicine companies that have disclosed their performance so far, the most outstanding market performance is Yiling Pharmaceutical, which holds the anti-epidemic "net celebrity" Chinese medicine Lianhua Qingwen series products.
According to the performance report recently released by Yiling Pharmaceutical, the company will achieve a total operating income of 8.
736 billion yuan in 2020, a year-on-year increase of 49.
97%, leading the ranks of listed Chinese medicine companies.
The net profit attributable to shareholders of listed companies also reached 1.
220 billion yuan, a year-on-year increase of 101.
12%.

 

　　Some analysts pointed out that the outstanding performance of Yiling Pharmaceutical is obviously related to the rapid growth in sales revenue of Lianhua Qingwen products compared with the same period last year.
Yiling Pharmaceuticals admitted frankly that during the reporting period, the brand awareness of Lianhua Qingwen products has been greatly improved, the domestic market demand has increased significantly, and sales have been achieved in more than ten registered overseas countries.
However, it is worth noting that Yiling Pharmaceutical also stated that the first prize of the National Science and Technology Progress Award has also increased its influence in the cardiovascular and cerebrovascular products market, and the sales of its cardiovascular and cerebrovascular products have increased significantly.

 

　　The report card of Zuoli Pharmaceutical, which ranks second in the pre-increasing rate of net profit, is also remarkable.
Although the net profit attributable to shareholders of listed companies in 2020 is expected to be only 85 million to 95 million yuan, the year-on-year growth can reach 232.
12%-271.
2%.
Zuoli Pharmaceuticals stated in the performance forecast that taking advantage of the core products Wuling Capsules, Bailing Tablets, and Lingze Tablets to enter the National Essential Drug List, increasing market investment and the development and coverage of terminal medical institutions are the main factors for performance growth.
.
From the perspective of the industry, in the face of changes in the external environment, focusing on the main business and grasping policy opportunities are the keys to the rapid growth of Zuoli Pharmaceutical's performance.

 

　　Although the predicted performance of net profit of 400 million to 480 million yuan, a year-on-year increase of 215.
73% to 238.
88%, Conba also entered the queue with a net profit increase of more than 100%, but from the perspective of revenue, it has a year-on-year increase of 12 The decline of% is not optimistic.
This is closely related to the listing of Danshen Ligustrazine Injection, the main product of subsidiary Guizhou Beite Pharmaceutical, in the national key monitoring catalog of rational use of drugs and the policy of recalling the medical insurance catalog.
Severely affected by the policy, the sales revenue of this product in 2020 will drop by about 1.
27 billion yuan year-on-year, a decrease of about 91.
4%.
However, Conba is also actively seeking to break through.
In addition to proactively adjusting and optimizing its business and product structure, focusing on expanding the self-health product business including over-the-counter drugs and consumer health products, it is also accelerating the development of new online retail business and trying its best to digest the factors.
Negative effects caused by policies and the epidemic.

 

　　Representatives of the National People's Congress suggest speeding up the collection of traditional Chinese medicine and formula granules

 

　　Traditional Chinese medicine is the advantage and characteristic of my country's health undertakings.
With the support of many national and local policies, the Chinese medicine industry is continuously developing.
Public data shows that the market size of Chinese patent medicines has increased from 625.
2 billion yuan in 2015 to 814.
9 billion yuan in 2019.
In accordance with this trend, the industry expects that the market size of proprietary Chinese medicines in 2022 is expected to exceed the trillion yuan mark.

 

　　And the traditional Chinese medicine formula granules, which have been piloted for 20 years and will soon usher in "regularity", will undoubtedly add another heavy assist to the Chinese medicine industry.
In February this year, in order to strengthen the management of traditional Chinese medicine formula granules, standardize the production of Chinese medicine formula granules, guide the healthy development of the industry, and better meet the clinical needs of Chinese medicine, the State Food and Drug Administration, the State Administration of Traditional Chinese Medicine, the National Health Commission, and the National Medical Insurance Administration The department jointly issued the "Announcement on Ending the Pilot Work of Chinese Medicine Formula Granules" (No.
22 of 2021).
Chinese medicine formula granules are subject to record management and cannot be sold outside medical institutions.

 

　　According to the National Pharmacopoeia Commission, the draft national drug standard for 160 Chinese medicine formula granules has been publicized and will be submitted to the National Drug Administration for approval and promulgation in the near future.
Some analysts pointed out that the promulgation of national standards for Chinese medicine formula granules may change the competitive landscape of this tens of billions market.
At the time when the "Two Sessions" are about to begin, according to China Securities Network, the National People's Congress and Chenguang Bio-Chairman Lu Qingguo intends to make suggestions at this year's national "Two Sessions" to speed up the entry of Chinese medicines and formula particles into centralized procurement.

 

　　Lu Qingguo said that the production of traditional Chinese medicine is small, scattered, and chaotic.
A pharmaceutical factory has dozens of varieties and tens of millions of sales.
The phenomenon of vicious competition, low-level duplication, emphasis on marketing, neglect of technology, and neglect of management is widespread.
Government supervision has increased the workload and difficulty.
The implementation of centralized procurement bidding for traditional Chinese medicines can effectively promote the large-scale production and operation of traditional Chinese medicine companies, reduce the cost of traditional Chinese medicine drugs, and enable Chinese medicine companies to achieve healthy development while focusing on management and technological progress, thereby promoting the healthy development of the Chinese medicine industry.
The proposal is to create conditions as soon as possible to allow proprietary Chinese medicines to enter the mechanism of centralized drug bidding and procurement, so that more traditional Chinese medicine manufacturers can participate in the competition fairly; improve the standard system, include traditional Chinese medicine formula granules into the drug centralized pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding procurement system, and promote traditional Chinese medicine formulations Better development of particles.

 

　　From the perspective of the industry, the policy of mass procurement of drugs has achieved remarkable results.
It has not only greatly saved medical insurance expenses and solved the problem of falsely high drug prices, but also eliminated the prevalence of rebates in the process of drug purchase and sales and guided drug manufacturers to dilute marketing and strengthen management.
Play an important role.
Although Zhejiang Jinhua, Qinghai, Liaoning, Henan and other provinces and cities have all launched trials of mass procurement of proprietary Chinese medicines, which has provided necessary experience for the procurement of Chinese patent medicines into the country, the relevant person in charge of the National Medical Insurance Bureau also stated that biosimilars and proprietary Chinese medicines are included Centralized procurement is "no doubt", but at present, it remains to be seen by the industry whether the conditions and time for Chinese medicine and formula granules to enter mass procurement have matured.

 

　　Provincial documents and pilot enterprises of Chinese medicine formula granules in some provinces and cities in my country